Skip to main content

Table 2 Comparison of endocrine and gynecologic diagnoses at adulthood

From: Gonadotropin releasing hormone analogue treatment of central precocious puberty is not associated with altered prevalence of polycystic ovary syndrome: a single center cohort study

Parameter GnRHa treatment
N = 27
No treatment
N = 24
P value
Hypothyroidism 1 (3.7) 1 (4.2) 1.00
Osteoporosis 0 1 (4.2) 0.471
Hyperinsulinism 1 (3.7) 0 1.00
Height (cm) 160.8 ± 4.6 (152–170) 154.8 ± 10.2 (130–170) 0.026
Delta height compared to mid-parental height -2.8 ± 5.1 (-13-(+ 16.5)) -6.3 ± 7.4 (-24-(+ 2)) 0.154
BMI (kg/m2) 24.8 ± 5.6 (19.4–40.0) 23.6 ± 3.4 (14.4–30.9) 0.865
PCOS diagnosisa 7 (25.9) 3 (12.5) 0.300
Hyper-androgenismb 8 (29.6) 7 (29.2) 0.971
Menorrhagia 2 (7.4) 4 (16.7) 0.402
Metrorrhagia 1 (3.7) 2 (8.3) 0.596
Menses    0.671
 Regular 17 (63.0) 17 (70.8)  
 Oligomenorrhea 8 (29.6) 7 (29.2)  
 Amenorrhea 2 (7.4) 0  
  1. Data presented as Mean ± SD or n (%)
  2. Note: PCOS Polycystic Ovary Syndrome, BMI Body Mass Index
  3. a According to the Androgen Excess Society Criteria (2006)
  4. b Either clinical or laboratory based hyperandrogenism diagnosis